Tat-Beclin-1 Peptide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Enhancing Hepatic Autophagy
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212372 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Chun-Liang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Taipei Veterans General Hospital, Taipei 112, Taiwan. Hauptthemen laut MEDLINE: Autophagy, Beclin-1, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Far Eastern Memorial Hospital—National Taiwan University Hospital Joint Research Program.
Abstract (Originalsprache)
Autophagy plays a crucial role in hepatic lipid metabolism, making it a key therapeutic target for addressing metabolic dysfunction-associated steatotic liver disease (MASLD). This study evaluates the efficacy of the Tat-Beclin-1 (TB-1) peptide, a specific autophagy inducer, in mitigating MASLD. Initially, we examined the impact of the TB-1 peptide on autophagic activity and intracellular lipid metabolism in HepG2 cells treated with oleic acid, using a Tat scrambled (TS) control peptide for comparison. Subsequently, we established a MASLD mouse model by feeding a high-fat diet (HFD) for 16 weeks, followed by intraperitoneal administration of TB-1 or TS. Assessments included liver histopathology, serum biochemistry, and autophagy marker analysis. Our findings indicate that the TB-1 peptide significantly increased the LC3II/β-actin ratio in a dose- and time-dependent manner while promoting the expression of key autophagy markers Beclin-1 and ATG5-12. Furthermore, TB-1 treatment led to a marked reduction in both the size and number of lipid droplets in HepG2 cells. In vivo, HFD-fed mice exhibited increased liver weight, elevated serum alanine aminotransferase levels, and impaired oral glucose tolerance. TB-1 administration effectively mitigated these hepatic and metabolic disturbances. Histological analysis further revealed a substantial reduction in the severity of hepatic steatosis and fibrosis in TB-1-treated mice compared to TS controls. In conclusion, the TB-1 peptide shows significant potential in reducing the severity of MASLD in both HepG2 cell models and HFD-induced MASLD mouse models. Enhancing autophagy through TB-1 represents a promising therapeutic strategy for treating MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Taipei Veterans General Hospital, Taipei 112, Taiwan.
- Department of Healthcare Administration, Asia Eastern University of Science and Technology, New Taipei City 220, Taiwan.
- Department of Pediatrics, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
- Department of Pediatrics, National Taiwan University Hospital, Taipei 100, Taiwan.
ORCID-Profile: Chun-Liang Chen, Chi-Chien Wu, Yu-Cheng Lin
Förderung
- National Science and Technology Council
- Far Eastern Memorial Hospital—National Taiwan University Hospital Joint Research Program
Zitieren
APA
Chen, C. L., Huang, F. F., Lin, H. F., Wu, C. C., Ni, Y. H., & Lin, Y. C. (2024). Tat-Beclin-1 Peptide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Enhancing Hepatic Autophagy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212372
Vancouver
Chen CL, Huang FF, Lin HF, Wu CC, Ni YH, Lin YC. Tat-Beclin-1 Peptide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Enhancing Hepatic Autophagy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212372
BibTeX
@article{Chen2024,
author = {Chen, Chun-Liang and Huang, Fen-Fen and Lin, Hsueh-Fang and Wu, Chi-Chien and Ni, Yen-Hsuan and Lin, Yu-Cheng},
title = {Tat-Beclin-1 Peptide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Enhancing Hepatic Autophagy},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212372}
}
EUVIMED